Andrew Nicholas Kozlov, MD
Nuclear Medicine · Salt Lake City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · University of Utah Adult Services · 1,758 clinicians in this group
Looking this up.
Hospitals listed: University of Utah Hospital and Clinics. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kozlov’s office at (801) 213-2995 to ask if they take your plan before you enroll.
State licence records
1 licence
- Florida ME150521Medical Doctor · since 2021 · expires 2027-01-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
3 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Education
- University of Florida2009–2014
Residency and fellowship
- Stanford University School of Medicine, OTHERStanford, CA · 2019–2020
- Hospital of the University of Pennsylvania, DIAGNOSTIC RADIOLOGYPhiladelphia, PA · 2015–2019
- St. Francis Hospital, TRANSITIONAL YEAREvanston, IL · 2014–2015
What else the board holds
Also licensed in
States the clinician told their board they are also licensed in. Only the states we check are verified.
California · Illinois · Oregon · Pennsylvania
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- University of Utah Hospital and ClinicsSalt Lake City, UTAcute Care Hospital · Government - State · Has an emergency department · Birthing-friendlyPart of University of Utah Hospitals and Clinics, which runs 2 hospitalsHome of Huntsman Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.603, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.55, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.518, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.595, Oct 2024 – Sep 2025Better than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 8.8 (7.3 to 10.3) · 1,119 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for University of Utah Hospital and Clinics
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 1 worse of 8 measures. Readmissions: 2 better, 8 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.603 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.55 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.518 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.595 | Better | Oct 2024 – Sep 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.8 (7.3 to 10.3) · 1,119 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.78 (0.03 to 1.53) · 3,231 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.6 to 1.22) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 156.56 (123.99 to 189.13) · 297 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.3 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 168 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 423 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.7 · 347 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.8 · 506 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,004 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0.02 to 0.37) · 11,361 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.08 to 0.43) · 12,089 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.06 (2.7 to 5.41) · 4,881 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.58 (0 to 3.27) · 204 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.55 (1.5 to 3.59) · 4,443 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.76 (0 to 15.4) · 212 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.49 (1.4 to 9.58) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.88 (0.63 to 3.14) · 1,317 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.5 (0.08 to 0.92) · 10,150 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.8 · 289 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.204 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.738 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.5 · 213 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 17.5 · 664 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.4 · 180 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -34.8 · 478 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -7 · 374 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 535 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.8 (4.6 to 7) · 1,119 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 310 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.2 · 113 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.9 to 15.8) · 2,684 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.2) · 2,156 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,497 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 78% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 61% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$50,444
Medicare paid this office $50,444 for 969 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Screening mammography | 239 | $8,156 | $34 |
| Screening 3d breast mammography | 239 | $6,404 | $27 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 70 | $5,566 | $78 |
| Screening mammography | 111 | $4,203 | $38 |
| Screening 3d breast mammography | 111 | $3,079 | $28 |
See all 18 services
| Screening mammography | 239 | $8,156 | $34 |
| Screening 3d breast mammography | 239 | $6,404 | $27 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 70 | $5,566 | $78 |
| Screening mammography | 111 | $4,203 | $38 |
| Screening 3d breast mammography | 111 | $3,079 | $28 |
| Biopsy of breast and placement of locating device using ultrasound, first growth | 21 | $2,245 | $107 |
| Dxa bone density measurement of hip, pelvis, spine | 178 | $1,588 | $9 |
| Biopsy of breast and placement of locating device using x-ray with needle, first growth | 13 | $1,586 | $122 |
| Limited ultrasound scan of 1 breast | 66 | $1,472 | $22 |
| Mri scan of both breasts | 18 | $1,327 | $74 |
| Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 65 | $1,268 | $20 |
| Diagnostic mammography of 1 breast | 40 | $1,050 | $26 |
| Nuclear medicine study of bone and/or joint whole body | 30 | $926 | $28 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 24 | $910 | $38 |
| Diagnostic mammography of both breasts | 25 | $804 | $32 |
| Placement of locating device in breast using ultrasound guidance, first growth | 14 | $756 | $54 |
| Ct scan of chest with contrast | 18 | $722 | $40 |
| Dxa bone density measurement of hip, pelvis, spine | 71 | $633 | $9 |
Who their Medicare patients are
969 Original Medicare patients in 2024. Average age 73 · Under 65 5% · 85 and older 6% · Women 81% · Also on Medicaid 8% · Health risk score 1.26. At or below the middle of the specialty; the typical nuclear medicine clinician is at 1.94.
Conditions among them: High blood pressure 63% · Depression 34% · Cancer 32% · Diabetes 23% · Coronary heart disease 16% · Chronic kidney disease 15% · Atrial fibrillation 13% · Heart failure 11% · COPD 8% · Stroke 7% · Dementia 5%.
The office billed $247,182, Medicare allowed $59,929 and paid $50,444; for 1,534 services of 55 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 969 | 1,534 | 73 | 1.26 | $247,182 | $50,444 |
| 2023 | 1,188 | 2,160 | 73 | 1.71 | $863,347 | $205,272 |
| 2022 | 2,655 | 5,601 | 72 | 2.11 | $3,825,483 | $860,292 |
| 2021 | 1,669 | 4,676 | 72 | 2.03 | $815,066 | $164,489 |
| 2020 | 486 | 774 | 70 | 2.03 | $82,588 | $22,606 |
| 2019 | 18 | 21 | 76 | 1.40 | $2,626 | $377 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 25 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 40 | $43,506 | $1,088 |
| Nuclear medicine study whole body with ct scan | 14 | $16,269 | $1,162 |
| Screening mammography | 339 | $12,143 | $36 |
| Screening 3d breast mammography | 339 | $9,658 | $28 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 34 | $7,997 | $235 |
| Screening mammography | 61 | $4,875 | $80 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 45 | $4,019 | $89 |
| Screening 3d breast mammography | 55 | $2,135 | $39 |
| Mri scan of both breasts | 23 | $1,811 | $79 |
| Dxa bone density measurement of hip, pelvis, spine | 150 | $1,395 | $9 |
| Diagnostic mammography of both breasts | 15 | $1,192 | $79 |
| Limited ultrasound scan of 1 breast | 42 | $1,110 | $26 |
| Nuclear medicine study of bone and/or joint whole body | 35 | $1,033 | $30 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 18 | $958 | $53 |
| Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 39 | $866 | $22 |
| X-ray of chest, 1 view | 110 | $820 | $7 |
| Limited ultrasound scan of 1 breast | 17 | $699 | $41 |
| Diagnostic mammography of 1 breast | 23 | $666 | $29 |
| Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 20 | $659 | $33 |
| Diagnostic mammography of both breasts | 17 | $632 | $37 |
| Dxa bone density measurement of hip, pelvis, spine | 31 | $613 | $20 |
| Nuclear medicine study of stomach to assess emptying | 15 | $439 | $29 |
| Nuclear medicine study of lung circulation | 15 | $412 | $27 |
| Nuclear medicine study of parathyroid | 11 | $307 | $28 |
| X-ray of abdomen, 1 view | 24 | $166 | $7 |
2022: 56 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 274 | $306,305 | $1,082 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 26 | $106,707 | $456 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 234 | $86,809 | $357 |
| Screening mammography | 432 | $55,088 | $128 |
| Fluciclovine f-18, diagnostic, 1 millicurie | 13 | $49,204 | $384 |
| Nuclear medicine study whole body with ct scan | 28 | $33,870 | $1,093 |
| Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries | 13 | $27,961 | $2,151 |
| Nuclear medicine study of brain with metabolic evaluation | 18 | $21,579 | $1,199 |
| Screening 3d breast mammography | 252 | $13,302 | $53 |
| Nuclear medicine study of bone and/or joint whole body | 41 | $8,923 | $212 |
| Diagnostic mammography of both breasts | 75 | $8,678 | $116 |
| Nuclear medicine study of stomach to assess emptying | 36 | $8,640 | $240 |
| Dxa bone density measurement of hip, pelvis, spine | 184 | $6,703 | $36 |
| Diagnostic mammography of 1 breast | 70 | $6,536 | $90 |
| X-ray of chest, 1 view | 589 | $5,967 | $7 |
| Nuclear medicine study of liver and bile duct system with use of drugs | 17 | $5,351 | $315 |
| Technetium tc-99m mertiatide, diagnostic, per study dose, up to 15 millicuries | 16 | $4,872 | $305 |
| Limited ultrasound scan of 1 breast | 67 | $4,578 | $65 |
| Biopsy of breast and placement of locating device using x-ray with needle, first growth | 11 | $4,346 | $395 |
| Mri scan of both breasts | 15 | $4,325 | $288 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 15 | $4,309 | $287 |
| Nuclear medicine study of bone taken at different times | 15 | $3,592 | $239 |
| Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 85 | $3,514 | $41 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 49 | $3,074 | $63 |
| Nuclear medicine study of parathyroid | 12 | $2,149 | $179 |
| Nuclear medicine study of kidney, blood, flow, and function with drug administration | 16 | $2,100 | $131 |
| X-ray of chest, 2 views | 98 | $2,040 | $21 |
| Nuclear medicine study of parathyroid | 62 | $1,910 | $31 |
| Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 32 | $1,714 | $54 |
| Ct scan of chest without contrast | 16 | $1,652 | $103 |
| Injection, sincalide, 5 micrograms | 16 | $1,519 | None |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 38 | $1,517 | $40 |
| Ct scan of abdomen and pelvis with contrast | 20 | $1,433 | $72 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 51 | $1,324 | $25 |
| Nuclear medicine study of lung circulation | 40 | $1,267 | $28 |
| Ct scan head or brain without contrast | 38 | $1,182 | $31 |
| Ct scan of abdomen and pelvis without contrast | 16 | $1,092 | $68 |
| X-ray of abdomen, 1 view | 122 | $1,085 | $7 |
| Complete ultrasound scan of 1 breast | 11 | $1,078 | $98 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 12 | $1,053 | $88 |
| X-ray of chest, 2 views | 90 | $774 | $9 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 14 | $723 | $52 |
| Imaging for evaluation of swallowing function | 29 | $620 | $21 |
| Nuclear medicine study of bone and/or joint whole body | 18 | $594 | $31 |
| Nuclear medicine study of stomach to assess emptying | 20 | $551 | $28 |
| Nuclear medicine study of liver and bile duct system with use of drugs | 16 | $522 | $33 |
| Ct scan of chest without contrast | 11 | $454 | $41 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 22 | $392 | $18 |
| Injection, gadoteridol, (prohance multipack), per ml | 17 | $299 | $1 |
| X-ray of hip, 2-3 views | 31 | $267 | $9 |
| Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 22 | $204 | $9 |
| X-ray of foot, minimum of 3 views | 13 | $95 | $7 |
| X-ray of knee, 1-2 views | 13 | $93 | $7 |
| X-ray of shoulder, minimum of 2 views | 12 | $91 | $8 |
| X-ray of thigh bone, minimum 2 views | 11 | $80 | $7 |
| Injection, furosemide, up to 20 mg | 16 | $15 | None |
2021: 38 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 27 | $27,067 | $1,002 |
| Screening mammography | 140 | $17,944 | $128 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 25 | $9,500 | $380 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 68 | $6,692 | $94 |
| Screening mammography | 160 | $6,115 | $38 |
| Ct scan of chest without contrast | 53 | $5,767 | $109 |
| Screening 3d breast mammography | 85 | $4,569 | $54 |
| Screening 3d breast mammography | 137 | $4,151 | $30 |
| X-ray of chest, 1 view | 386 | $3,758 | $7 |
| Diagnostic mammography of both breasts | 23 | $2,928 | $127 |
| Limited ultrasound scan of 1 breast | 37 | $2,907 | $69 |
| Diagnostic mammography of 1 breast | 27 | $2,658 | $98 |
| Nuclear medicine study whole body with ct scan | 22 | $2,204 | $96 |
| Dxa bone density measurement of hip, pelvis, spine | 57 | $2,117 | $37 |
| Ct scan of abdomen and pelvis without contrast | 12 | $1,861 | $155 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 25 | $1,566 | $63 |
| Nuclear medicine study of bone and/or joint whole body | 35 | $1,347 | $34 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 13 | $1,249 | $96 |
| Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 27 | $1,168 | $43 |
| Ultrasound scan of head and neck soft tissue | 12 | $1,095 | $91 |
| X-ray of chest, 2 views | 44 | $1,088 | $25 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 18 | $1,030 | $57 |
| X-ray of abdomen, 1 view | 83 | $728 | $7 |
| Limited ultrasound scan of 1 breast | 24 | $618 | $25 |
| Nuclear medicine study of lymphatic system | 13 | $603 | $46 |
| Diagnostic mammography of both breasts | 20 | $584 | $29 |
| Diagnostic mammography of 1 breast | 18 | $578 | $30 |
| Imaging for evaluation of swallowing function | 24 | $513 | $21 |
| Ct scan head or brain without contrast | 15 | $462 | $31 |
| X-ray of chest, 2 views | 53 | $451 | $9 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 11 | $423 | $38 |
| Nuclear medicine study of parathyroid | 13 | $403 | $31 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 14 | $330 | $24 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 28 | $215 | $0 |
| X-ray of pelvis, 1-2 views | 16 | $112 | $7 |
| X-ray of knee, 1-2 views | 14 | $94 | $6 |
| X-ray of shoulder, minimum of 2 views | 11 | $91 | $8 |
| X-ray of thigh bone, minimum 2 views | 11 | $80 | $7 |
2020: 10 services
| Screening mammography | 169 | $6,719 | $40 |
| Screening 3d breast mammography | 138 | $4,295 | $31 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 25 | $2,378 | $95 |
| X-ray of chest, 1 view | 126 | $1,218 | $8 |
| Diagnostic mammography of both breasts | 19 | $707 | $37 |
| Limited ultrasound scan of 1 breast | 18 | $552 | $29 |
| Nuclear medicine study of bone and/or joint whole body | 15 | $530 | $35 |
| Diagnostic mammography of 1 breast | 12 | $441 | $34 |
| X-ray of chest, 2 views | 43 | $355 | $8 |
| X-ray of abdomen, 1 view | 30 | $351 | $8 |
2019: 1 service
| X-ray of chest, 2 views | 11 | $109 | $10 |
Medicaid work
$586 in 2023
Medicaid paid $586 for 186 billed services this clinician did in 2023, up to 38 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Radiologic examination, chest; single view | 130 | $391 |
| X-ray of abdomen, 1 view | 56 | $195 |
| 2023 | 186 | 2 | 38 | $586 |
| 2022 | 1,654 | 11 | 85 | $31,804 |
| 2021 | 936 | 7 | 96 | $6,758 |
| 2020 | 431 | 6 | 62 | $3,871 |
See the largest Medicaid services in earlier years
2022
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 14 | $11,548 |
| Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed | 336 | $9,751 |
| Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited | 124 | $2,832 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 16 | $2,554 |
| Radiologic examination, chest; single view | 716 | $1,763 |
| SCREENING DIGITAL BREAST TOMOSYNTHESIS BI | 120 | $1,344 |
| Radiologic examination, chest; 2 views | 96 | $697 |
| DIAGNOSTIC MAMMOGRAPHY COMPUTER-AIDED DETCJ BI | 19 | $686 |
| X-ray of abdomen, 1 view | 124 | $368 |
| Computed tomography, head or brain; without contrast material | 15 | $262 |
| Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 74 | $0 |
2021
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 26 | $2,135 |
| Radiologic examination, chest; single view | 562 | $1,802 |
| Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed | 111 | $1,641 |
| X-ray of abdomen, 1 view | 147 | $454 |
| Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited | 12 | $448 |
| Radiologic examination, chest; 2 views | 61 | $279 |
| SCREENING DIGITAL BREAST TOMOSYNTHESIS BI | 17 | $0 |
2020
| Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed | 98 | $1,768 |
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 14 | $927 |
| Radiologic examination, chest; single view | 234 | $896 |
| X-ray of abdomen, 1 view | 56 | $196 |
| Radiologic examination, chest; 2 views | 15 | $84 |
| SCREENING DIGITAL BREAST TOMOSYNTHESIS BI | 14 | $0 |
Money from drug and device companies
$191 in 2022
| 2022 | 1 | 1 | None | $191 |
| 2019 | 1 | 1 | None | $375 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GE HealthCare | None | $191 | 1 payment
|
See the published payment
| GE HealthCare | Meals · 2022-06-23 | None | $191 |
See earlier years (2019)
2019: $375
| Hologic | Selenia Dimensions | $375 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 92.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1093134702
- Licence
- FL ME150521Florida ME150521: Active
- Trained
- University of Florida College of Medicine, 2014
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Diagnostic radiology (2085R0202X)
- Mailing address
- 2700 University Square Dr, Tampa, FL, 33612
- NPI first listed
- 2014-04-09
- NPI last updated
- 2023-06-13
- NPI record certified
- 2023-06-13
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 355 Ridge Ave, Evanston, IL, 60202 · 300 Pasteur Dr, Stanford, CA, 94305
This office lists an electronic records connection.